SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic ...
K. O'Reilly et al., "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt," Cancer Res, 66:1500—8, 2006. (Cited in 95 papers) It's known that rapamycin inhibits ...
“This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.” Breast cancer morbidity is surging towards the peak ...
Sirolimus may be an effective treatment for patients with persistent cutaneous sarcoidosis. In a small clinical trial, 7 of 10 patients treated with sirolimus via oral solution had improvements in ...
A new research paper was published in Oncotarget's Volume 14 on May 19, 2023, entitled, "G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic ...
Metastatic breast cancer (mBC) remains an incurable disease, and most patients will experience disease progression during their treatment course. Although endocrine therapy remains the mainstay of ...
(A) The Venn diagram showed the distribution of the DEGs between circFKBP8(5S,6) and cFKBP8-regulated genes. (B, C) DEGs involved in the neuroactive ligand-receptor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback